Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-D-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder
Linda J. Bristow(Bristol-Myers Squibb (United States)), Michael Sinz(Rutgers, The State University of New Jersey), Pattipati S. Naidu(Bristol-Myers Squibb (India)), Arvind Mathur(Bristol-Myers Squibb (United States)), Deborah Keavy(MACOM (United States)), Bettadapura N. Srikumar(National Institute of Mental Health and Neurosciences), M. S. Paschapur(Bristol-Myers Squibb (India)), Jayakumar Warrier(Bristol-Myers Squibb (India)), Manjunath Ramarao(Bristol-Myers Squibb (United States)), Meenakshee Sinha(MACOM (United States)), Digavalli V. Sivarao(Bristol-Myers Squibb (United States)), Lawrence R. Marcin(Bristol-Myers Squibb (United States)), Tanmaya Bastia(Bristol-Myers Squibb (India)), Joseph Polino(MACOM (United States)), Raja Reddy Kallem(Texas Tech University), Mark Bookbinder(MACOM (United States)), Amy Newton(Bristol-Myers Squibb (United States)), Srinivasan Thangathirupathy(Bristol-Myers Squibb (India)), Thaddeus F. Molski(Circle (United States)), Jyoti Gulia(Bristol-Myers Squibb (India)), Rick L. Pieschl(MACOM (United States)), John D. Graef(Fulcrum Therapeutics (United States)), Dalton King(Circle (United States)), Lorin A. Thompson(DuPont (United States)), Narasimharaju Kalidindi(Bristol-Myers Squibb (India)), Jeffrey M. Brown(MACOM (United States)), Charlie Albright(Editas Medicine (United States)), James Kempson(Bristol-Myers Squibb (United States)), John E. Macor(Bristol-Myers Squibb (United States)), Reeba K. Vikramadithyan(Bristol-Myers Squibb (India)), Richard E. Olson(Los Alamos National Laboratory), Jean Simmermacher, Joanne J. Bronson(Bristol-Myers Squibb (United States)), Jayant Aher(Bristol-Myers Squibb (India)), Charulatha Sanmathi(Bristol-Myers Squibb (India)), Kuchibhotla Vijaya Kumar(MACOM (United States)), Yu-Wen Li(MACOM (United States)), Jianqing Li(Nanjing University of Chinese Medicine), Huiping Zhang(Huazhong University of Science and Technology), Michael R. Weed(MACOM (United States)), Alda Fernandes(MACOM (United States)), Imadul Islam(King Saud bin Abdulaziz University for Health Sciences), Eric Shields(Bristol-Myers Squibb (United States)), Kimberly Newberry(MACOM (United States))
Cited by 17
Related Papers
CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes
|Drug Metabolism and Disposition|2002|447
MEK inhibitors: The chemistry and biological activity of U0126, its analogs, and cyclization products
|Bioorganic & Medicinal Chemistry Letters|1998|406
RAGE potentiates Aβ‐induced perturbation of neuronal function in transgenic mice
|The EMBO Journal|2004|327
Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice
|Chemical Research in Toxicology|1998|312